Elan Pharmaceuticals, Inc. v. Mayo Foundation, 00-1467.

• Decision Date: 18 December 2002
• Docket Number: No. 00-1467.,00-1467.
• Parties: ELAN PHARMACEUTICALS, INC. and Athena Neurosciences, Inc., Plaintiffs-Appellants, v. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, Defendant-Appellee.
• Court: U.S. Court of Appeals — Federal Circuit

314 F.3d 1299

ELAN PHARMACEUTICALS, INC. and Athena Neurosciences, Inc., Plaintiffs-Appellants, v. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, Defendant-Appellee.

No. 00-1467.

United States Court of Appeals, Federal Circuit.

December 18, 2002.

Appealed from United States District Court for the Northern District of California, Judge William H. Alsup.

ON COMBINED PETITION FOR PANEL REHEARING AND REHEARING EN BANC

Lynn H. Pasahow, Fenwick & West LLP, of Palo Alto, CA, filed a response to the petition for rehearing for plaintiffs-appellants. Of counsel on the response were Beth H. Parker, and S. Christian Platt, Bingham McCutchen, LLP, of San Francisco, CA.

Robert E. Hillman, Fish & Richardson, P.C., of Boston, MA, filed a combined petition for panel rehearing and rehearing en banc for defendant-appellee. Of counsel on the petition were Shelley K. Wessels, Karen I. Boyd, and Kurtis D. MacFerrin, Fish & Richardson, P.C., of Redwood City, CA. Also of counsel was Chad A. Hanson, Fish & Richardson, P.C., of Minneapolis, MN.

ORDER

A combined petition for panel rehearing and rehearing en banc having been filed by the Appellee, a response thereto having been invited by the court and filed by the Appellants, the petition for panel rehearing having been referred to the panel that heard the appeal, thereafter the petition for rehearing en banc and response having been referred to the circuit judges who are in regular active service, and a poll having been requested and taken,

IT IS ORDERED THAT:

(1) The petition for panel rehearing is denied.

(2) The petition for rehearing en banc is granted.

(3) Acting en banc, the court vacates the panel's judgment and original opinion entered August 30, 2002, Elan Pharmaceuticals, Inc. v. Mayo Foundation, 304 F.3d 1221 (Fed.Cir.2002).